Results 111 to 120 of about 95,123 (282)

Data from Clinical <i>BRCA1/2</i> Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance

, 2023
Stephen J. Pettitt, Jessica Frankum, Marco Punta, Stefano Lise, John Alexander, Yi Chen, Timothy A. Yap, Syed Haider, Andrew Tutt, Christopher J. Lord   +9 more
openalex   +1 more source

Compliance of Dermatology Screening Visits Among Patients With Skin Cancer‐Predisposing Pathogenic Variants

JEADV Clinical Practice, EarlyView.
Patients with genetic variants that increase skin cancer risk are recommended to undergo regular dermatology screenings per National Comprehensive Cancer Network guidelines, but compliance is uncertain. In a retrospective study of 230 patients with such variants, compliance with screening visits significantly improved after visiting a Hereditary Cancer
Stephen J. Gadomski, Kevin S. Hughes, Jihad S. Obeid, Courtney Rowley, Graciela De Jesús   +4 more
wiley   +1 more source

CRISPR Enabled Precision Oncology: From Gene Editing to Tumor Microenvironment Remodeling

Med Research, EarlyView.
CRISPR technology has progressed from a prokaryotic immune system to a diverse suite of editing platforms, including Cas nucleases, base and prime editors, and RNA‐targeting enzymes. These advances enable precise genomic and epigenomic interventions, high‐throughput functional screening, and immune engineering.
Kailai Li, Peixin Huang, Yue Qian, Anqi Lin, Jingjun He, Junyi Shen, Li Chen, Kai Miao, Jian Zhang   +8 more
wiley   +1 more source

Germline and Somatic BRCA1/2 Mutations in 172 Chinese Women With Epithelial Ovarian Cancer

, 2020
Yan You, Lei Li, Junliang Lu, Huanwen Wu, Jing Wang, Jie Gao, Ming Wu, Zhiyong Liang   +7 more
openalex   +1 more source

From mechanism to phenotype: What fits in a basket trial

Epilepsia, EarlyView.
Kette D. Valente
wiley   +1 more source

Treatment Response and Outcomes of Prostate Cancer Patients Carrying the Germline MMS22L F722fs Mutation

The Prostate, EarlyView.
ABSTRACT Background Methyl Methanesulfonate‐Sensitivity Protein 22‐Like (MMS22L) plays a key role in homology‐directed DNA repair, and experimental models have shown that its loss confers sensitivity to Poly (ADP‐ribose) polymerase inhibitors (PARPi).
Mayuko Kanayama, Violet A. Daniels, Marta Gielzak, Alex Brame, Misop Han, Li Jia, Jianfeng Xu, Tamara L. Lotan, Mario A. Eisenberger, Catherine H. Marshall, Patrick C. Walsh, William B. Isaacs, Jun Luo   +12 more
wiley   +1 more source

Snapshots of Motion: A Novel Structural Intermediate Reveals Conserved Dynamics in Archaeal DNA Ligases

Proteins: Structure, Function, and Bioinformatics, EarlyView.
ABSTRACT We present the first x‐ray crystallographic structural evidence of an archaeal DNA ligase showing the AMP covalent adduct together with further cofactor hydrolysis, capturing a transient intermediary in the first step of the ligation reaction, triggered by the pyrophosphate hydrolysis.
A. X. Quintana‐Armas, E. Flores‐Hernández, C. Cardona‐Félix, E. Rudiño‐Piñera   +3 more
wiley   +1 more source

Liquid biopsy in genitourinary oncology: Current clinical applications and future prospects across prostate, bladder, and renal cancers

UroPrecision, EarlyView.
Abstract Liquid biopsy has emerged as a transformative approach in oncology, providing minimally invasive access to tumor‐derived biomarkers with applications across diagnosis, prognosis, therapeutic guidance, and disease monitoring. This literature review synthesizes evidence from 125 studies evaluating circulating tumor DNA, circulating tumor cells ...
Kirolos Eskandar
wiley   +1 more source

PSMA PET‐directed radiotherapy for prostate cancer: From precision planning to future innovations

VIEW, EarlyView.
Prostate‐specific membrane antigen (PSMA) positron emission tomography (PET) imaging enables highly sensitive detection of prostate cancer recurrence and precise lesion mapping. This review summarizes current evidence and emerging applications of PSMA PET in radiotherapy, including diagnostic staging, target delineation, adaptive planning, and outcome ...
Wenpeng Huang, Jessica C. Hsu, Ruobing Li, Kexin Lan, Xin Qi, Yuchun Wei, Weibo Cai, Hongzhen Li   +7 more
wiley   +1 more source

Mass spectrometry‐based mitochondrial proteomics for cancer biomarker discovery

VIEW, EarlyView.
Figure.1 Schematic diagram of MS‐based mitochondrial proteomics for cancer biomarker discovery. The workflow highlights the integration of advanced technological platforms in mitochondrial proteomics and their application in cancer biomarker discovery.
Zheng Cao, ZiKun Song, Weijie Zhou, Xiaohui Liu, Yanling Liu, Peng R. Chen, Kun Qian   +6 more
wiley   +1 more source